FIGURE 2.

SHYS treatment alleviated the body weight loss, hyperglycemia, proteinuria, pathological changes in kidney and inflammatory response in DN rats. (A) SHYS treatment alleviated the body weight loss in DN model rats. (B) SHYS treatment decreased the FBG in DN rats. (C) SHYS treatment decreased the level of 24-h urine protein. (D) H and E staining indicated that SHYS treatment significantly improved the pathological changes of kidney in DN rats (200 ×) (E–H) Masson (E,G) and Sirius red (F,H) staining indicated that SHYS treatment significantly decreased collagen depositions in kidney (200 ×). (I) SHYS treatment decreased the levels of pro-inflammatory cytokines in renal tissue homogenates. Control, Model, Irbesartan, SHYS low-dose, SHYS middle-dose and SHYS high-dose (n = 10 per group) groups. Data are presented as the mean ± SD. ^##: p < 0.01 as compared to the Control group; ^*: p < 0.05 as compared to the Model group; ^**: p < 0.01 as compared to the Model group; ^△: p < 0.05 as compared to the Irbesartan group; ^△△: p < 0.01 as compared to the Irbesartan group; ^: p < 0.05 as compared to the SHYS low-dose group; ^^: p < 0.01 as compared to the SHYS low-dose group